Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Has Average Price Target of $108.18 According to Analysts

Halozyme Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Halozyme Therapeutics a consensus “Hold” rating: seven recommend buying, five holding, and one selling. Their average 12-month price target is $108.18, with recent targets ranging from $79 to $149.
  • Halozyme beat quarterly estimates, reporting earnings of $2.39 per share versus $2.30 expected, while revenue rose 39.1% year over year to $492.97 million.
  • The CEO and a director recently sold shares under pre-arranged trading plans; insiders sold 149,226 shares worth about $15.7 million over the past quarter.
  • Five stocks to consider instead of Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has received an average recommendation of "Hold" from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $108.18.

A number of brokerages have weighed in on HALO. TD Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Monday. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Tuesday, November 3rd. Leerink Partners downgraded Halozyme Therapeutics from an "outperform" rating to a "hold" rating and lifted their price target for the company from $110.00 to $117.00 in a research report on Friday, November 6th. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a report on Friday, October 16th. Finally, Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a "market outperform" rating in a research report on Friday, November 6th.

View Our Latest Report on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $95.80 on Thursday. The company's 50 day simple moving average is $113.81 and its two-hundred day simple moving average is $85.87. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The stock has a market capitalization of $10.92 billion, a PE ratio of 24.38, a P/E/G ratio of 0.36 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same period in the previous year, the business earned $1.72 EPS. The business's revenue for the quarter was up 39.1% on a year-over-year basis. Analysts predict that Halozyme Therapeutics will post 8.34 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $98.38, for a total value of $1,967,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at $75,534,196.40. This represents a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total transaction of $482,150.00. Following the sale, the director directly owned 48,609 shares of the company's stock, valued at $4,687,365.87. This represents a 9.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 149,226 shares of company stock valued at $15,744,643. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Horizon Investment Services LLC bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $2,254,000. WINTON GROUP Ltd lifted its stake in Halozyme Therapeutics by 704.6% in the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company's stock worth $4,723,000 after acquiring an additional 52,848 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Halozyme Therapeutics in the second quarter valued at $1,025,000. Great Lakes Advisors LLC bought a new stake in Halozyme Therapeutics in the second quarter valued at $2,821,000. Finally, Chase Investment Counsel Corp purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at $2,035,000. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Recommended Stories

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Halozyme Therapeutics Right Now?

Before you consider Halozyme Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.

While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines